Details of the Drug Reposition

General Information of This Drug (ID: DMLB81S)

• Drug Name: Paclitaxel (DMLB81S)
• Synonyms: 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-b; 7-epi-Paclitaxel; ABI-007; Abraxane; Capxol; Ebetaxel; EmPAC; Genaxol; Genetaxyl; Genexol; Intaxel; LipoPac; OncoGel; Onxol; Paclitaxel (Taxol); Paxceed; Paxene; Plaxicel; TAXOL; TaxAlbin; Taxol A; Xorane; Yewtaxan; Zisu; nab-paclitaxel; paclitaxel
• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

18 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Testicular germ cell tumor	DIS5RN24	N.A.	Approved	[1]
Primary peritoneal carcinoma	DISKYEDV	N.A.	Approved	[1]
Ovarian serous cystadenocarcinoma	DISMYAWR	N.A.	Approved	[1]
Ovarian neoplasm	DISEAFTY	N.A.	Approved	[1]
Lung adenocarcinoma	DISD51WR	N.A.	Approved	[1]
Fallopian tube neoplasm	DISHMMF2	N.A.	Approved	[1]
Extragonadal germ cell tumor	DISE6LY9	N.A.	Approved	[1]
Breast carcinoma	DIS2UE88	N.A.	Approved	[1]
Kaposi sarcoma	DISC1H1Z	2B57	Approved	[1]
Epithelial ovarian cancer	DIS56MH2	2B5D	Approved	[1]
Gastroesophageal junction adenocarcinoma	DISCVPML	2B71	Approved	[1]
Pancreatic ductal carcinoma	DIS26F9Q	2C10.0	Approved	[1]
Non-small-cell lung cancer	DIS5Y6R9	2C25.Y	Approved	[1]
Cutaneous squamous cell carcinoma	DIS3LXUG	2C30	Approved	[1]
Inflammatory breast cancer	DIS3QRWA	2C62	Approved	[1]
Urethral cancer	DISDWYSE	2C93	Approved	[1]
Ocular hypertension	DISC2BT9	9C61.01	Approved	[1]
Pain	DIS4RWOW	MG30-MG3Z	Approved	[1]

2 Withdrawn Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Papillary serous cystadenocarcinoma	DISZV6Z3	N.A.	Withdrawn	[2]
Ovarian cancer	DISZJHAP	2C73	Withdrawn	[3]

1 Discontinued in Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Upper tract urothelial carcinoma	DISTE2ZH	N.A.	Discontinued in Phase 3	[4]

7 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Ovarian serous adenocarcinoma	DISSU72Z	N.A.	Discontinued in Phase 2	[5]
Primary peritoneal serous adenocarcinoma	DISNCHKN	N.A.	Discontinued in Phase 2	[6]
Esophageal adenocarcinoma	DISODWFP	N.A.	Discontinued in Phase 2	[7]
Thyroid gland undifferentiated (anaplastic) carcinoma	DISYBB1W	N.A.	Discontinued in Phase 2	[8]
Squamous cell carcinoma	DISQVIFL	2B60-2D01	Discontinued in Phase 2	[9]
Metastatic melanoma	DISSL43L	2E2Z	Discontinued in Phase 2	[10]
High blood pressure	DISY2OHH	BA00	Discontinued in Phase 2	[8]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Lung large cell carcinoma	DISUG64F	N.A.	Investigative	[1]

References

• [1] Paclitaxel FDA Label
• [2] ClinicalTrials.gov (NCT01763541) Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading
• [3] Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia
• [4] The Study of Nasonex Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)
• [5] Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes
• [6] Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment
• [7] A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFN-2A in Stage III or IV Ovarian Cancer
• [8] ClinicalTrials.gov (NCT01652014) Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
• [9] Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
• [10] Bisoprolol in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease